Dysport drug for treatment of cervical dystonia launched in the United States

Christophe Jean, Executive Vice President, Operations of the Ipsen Group said: “The launch of Dysport^® in its therapeutic indication for the treatment of cervical dystonia in the United States is undoubtedly a significant milestone to strengthen Ipsen's presence in North America. We are very pleased to be able to offer physicians a new and important treatment option for their patients suffering from cervical dystonia. Dysport^®, together with Somatuline^® and Increlex^®, becomes Ipsen’s third product to be available globally. With the achievement of this key milestone, I wish to congratulate and thank the teams that are making this launch a reality thanks to their hard work and dedication reflective of an efficient organization.”